London · Delayed Price · Currency is GBP · Price in GBX Sareum Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Interim results show stable expenses, a GBP 1.65m loss, and GBP 2.5m cash. 1801 advances toward phase II, 1802 is prepped for licensing, and SRA737 is actively marketed with extended IP. CNS and business development efforts are progressing.
Fiscal Year 2025
-
The meeting covered operational progress, financials, and strategic plans, with all resolutions passed by strong majorities. SDC-1801 advances toward phase II, while SRA737 and SDC-1802 are prioritized for partnering. Shareholders raised concerns about communication, funding, and board share purchases.
-
Pipeline progress continues with a focus on STC-1801, despite a toxicology study setback unrelated to the drug. Operating loss narrowed to under £3 million, with £3.5 million in cash, and partnering remains key for late-stage development.
-
Regained control of SRA737, expanded the clinical pipeline, and completed a positive phase I trial for SDC-1801. Operating expenses and losses decreased year-over-year, with a strong cash position supporting ongoing development and active licensing discussions.
Fiscal Year 2024
-
All AGM resolutions were passed, including director re-elections and share authorities. The board highlighted the completion of a key clinical study, outlined plans for advancing pipeline assets, and addressed questions on strategy, partnerships, and data disclosure.
-
Completed a successful Phase 1 trial for SDC-1801 with strong safety and efficacy data, raised £4.4 million to fund Phase 2 readiness, and awaits milestone updates on SRA737. Operating loss increased due to higher clinical trial costs, and the company remains open to partnering or advancing independently.